- Home
- PFO vs ANVS Comparison
PFO vs ANVS Comparison
Compare PFO & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFO | ANVS |
|---|---|---|
| Founded | 1991 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.3M | 111.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PFO | ANVS |
|---|---|---|
| Price | $9.69 | $2.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 31.8K | ★ 522.5K |
| Earning Date | 01-01-0001 | 03-20-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.90 | $1.11 |
| 52 Week High | $8.51 | $5.50 |
Technical Indicators
Market Signals| Indicator | PFO | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 64.84 | 33.23 |
| Support Level | $9.64 | $2.60 |
| Resistance Level | $9.63 | $2.81 |
| Average True Range (ATR) | 0.06 | 0.22 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 85.71 | 8.24 |
Price Performance
Historical ComparisonAbout PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.